News

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J

Barington Capital Group and Thor Equities called on Macy's to create a real estate subsidiary and limit its capital expenditures.

“Awe of ‘American exceptionalism’ in markets has now gone too far,” said Ruchir Sharma, chair of Rockefeller International.

The first phase will connect the Energy Transfer pipeline and storage network, linking to the Dallas/Ft. Worth Metroplex.

On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. Consistent with Beam’s previously announced data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases i

Omnicom is buying Interpublic Group in a stock-for-stock deal that will create the largest ad agency in the world with combined annual revenue of almost $26 billion. The names may be unfamiliar to many Americans, but some of their marketing campaigns are iconic. The combined company will be worth more than $30 billion.

Analysts have an unusual challenge in assessing how CEO Elon Musk’s relationship with President-elect Donald Trump will impact Tesla.